Liquidia Corporation

We are deeply passionate and committed to the discovery, engineering, and development required to bring novel therapies to patients who need them most, and to the healthcare providers who care for them. Our current drive is toward improving the treatment of pulmonary arterial hypertension (PAH).

We will continue to combine our proprietary, innovative PRINT Technology with new and established medications, offering the potential for both better precision and improved clinical outcomes.

News Releases

NOV 07 2023

Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oral arguments in appeal of ‘793 PTAB decision set for December 4, 2023 PDUFA goal date to add PH-ILD indication to YUTREPIA label is January 24, 2024 Hired sales force in preparation of potential positive legal and regulatory outcomes MORRISVILLE, N.C. , Nov.
OCT 31 2023

Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023

MORRISVILLE, N.C. , Oct. 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023 . The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a

btn News